Lower-frequency signal: Viking conquest ahead in obesity?

An expert with 35 years of experience in the obesity field called Viking Therapeutics Inc.’s prospect VK-2735 “among the best that we’ve seen,” and shares (NASDAQ:VKTX) reflected as much, closing Sept. 22 at $40.85, up $10.74, or 35.7%, having traded as high as $41.13.